SCHEMBL2138274

SCHEMBL2138274

FC(F)(F)c1ccnc(-c2ccccc2)n1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 3/20 0.56
SYK P43405 7/20 0.51
LMNA P02545 1/20 0.49
POLB P06746 1/20 0.49
SLC6A7 Q99884 1/20 0.46
NPSR1 Q6W5P4 1/20 0.44
TAS2R14 Q9NYV8 1/20 0.43
IDH1 O75874 2/20 0.42
KDM4E B2RXH2 2/20 0.42
HSD17B10 Q99714 1/20 0.42
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
PKM P14618 1/20 0.41
IDH2 P48735 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28213510 0.83 KMT2A (0.53) HDAC4LMNANPSR1IDH1KDM4E
SCHEMBL23683043 0.83 HDAC4 (0.68) HDAC4SYKLMNAPOLBSLC6A7
SCHEMBL31516632 0.82 CYP2A6 (0.56) SYKLMNAKDM4EHSD17B10MAPT
SCHEMBL28135251 0.81 MEN1 (0.51) HDAC4SYKIDH1KDM4EMEN1
SCHEMBL533189 0.81 HDAC4 (0.47) HDAC4SYKIDH1IDH2
SCHEMBL22027742 0.81 HDAC4 (0.47) HDAC4SYKIDH1MEN1KMT2A
SCHEMBL4172326 0.81 SYK (0.56) HDAC4SYKSLC6A7TAS2R14
SCHEMBL16420290 0.81 SYK (0.51) HDAC4SYKLMNAPOLBNPSR1
SCHEMBL31162575 0.81 SYK (0.51) HDAC4SYKLMNAPOLBNPSR1
SCHEMBL22027762 0.80 SYK (0.45) HDAC4SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116554230-A Iridium complex containing trifluoromethyl substituted oxadiazole amide ligand and preparation method and application thereof 商丘师范学院 2023-08-08 CN disclosed
US-8242278-B2 Process for producing biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-08-14 US disclosed
US-20120101278-A1 PROCESS FOR PRODUCING BIARYL COMPOUND HAGIYA KOJI (JP) 2012-04-26 US disclosed
EP-1473286-B1 PROCESS FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL CO (JP) 2009-11-04 EP disclosed
US-20090216017-A1 PROCESS FOR PRODUCING BIARYL COMPOUND HAGIYA KOJI 2009-08-27 US disclosed
US-7554000-B2 Process for producing biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-30 US disclosed
CN-1303043-C Process for producing biaryl compound SUMITOMO CHEMICAL CO (JP) 2007-03-07 CN disclosed
CN-1642879-A Process for preparing diaryl compounds SUMITOMO CHEMICAL CO (JP) 2005-07-20 CN disclosed
US-20050096471-A1 Process for producing biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-05-05 US disclosed
EP-1473286-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2004-11-03 EP disclosed
EP-0817773-B1 PYRIMIDINE COMPOUNDS QINETIQ LTD (GB) 2002-06-12 EP disclosed
US-6121448-A LIQUID CRYSTALLINE COMPOUNDS THE SECRETARY OF STATE FOR DEFENCE IN HER BRITTANIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) 2000-09-19 US disclosed
US-5986096-A REACTION OF HYDROGEN IODIDE WITH CHLORO-5-BROMOPYRIMIDINE THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S A GOVERNMENT OF THE U.K. OF GT. BRITAIN & N. IRELAND OF DEFENCE EVALUATION & RESEARCH AGENCY (GB) 1999-11-16 US disclosed
WO-1996030344-A9 PYRIMIDINE COMPOUNDS 1999-02-11 WO disclosed
EP-0817773-A2 PYRIMIDINE COMPOUNDS THE SECRETARY OF STATE FOR DEFENCE (GB) 1998-01-14 EP disclosed
WO-1996030344-A2 PYRIMIDINE COMPOUNDS THE SECRETARY OF STATE FOR DEFENCE (GB) 1996-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101278-A1 PROCESS FOR PRODUCING BIARYL COMPOUND PPOX, CAT, TYR HDAC4 738/4885SYK 2184/4885LMNA 3829/4885
US-20090216017-A1 PROCESS FOR PRODUCING BIARYL COMPOUND PPOX, CAT, TYR HDAC4 738/4885SYK 2184/4885LMNA 3829/4885
US-20050096471-A1 Process for producing biaryl compound PPOX, CAT, TYR HDAC4 738/4885SYK 2184/4885LMNA 3829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.